Evidence map›Paper›PMID 20008935›Full record

ArticleGenes & development2009

miR-19 is a key oncogenic component of mir-17-92.

Virginie Olive, Margaux J Bennett, James C Walker, Cong Ma, Iris Jiang, Carlos Cordon-Cardo, Qi-Jing Li, Scott W Lowe, Gregory J Hannon, Lin He

Open access · diamondAbstract read
In one paragraph

Article in Genes & development, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 364 papers.

0numbers the graph read from it
0cells of the map it votes in
364citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

364 citing papers in PubMed, 583 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Cancers · 2026
    Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. CAMKIIδ Reinforces Lipid Metabolism and Promotes the Development of B Cell Lymphoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

304 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Virginie OliveDivision of Cellular and Developmental Biology, Department of Molecular and Cell Biology, University of California at Berkeley, Berkeley, California 94705, USA.
Margaux J Bennett
James C Walker
Cong Ma
Iris Jiang
Carlos Cordon-Cardo
Qi-Jing Li
Scott W Lowe
Gregory J Hannon
Lin He
University of California, Berkeley · USCold Spring Harbor Laboratory · USCancer Research Center · USDuke University Hospital · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Functions of microRNAs in lymphomagenesisR00CA126186 · NCI · UNIVERSITY OF CALIFORNIA BERKELEY · PI HE, LIN · 2009 to 2011
$709k
NCI NIH HHS P30 CA008748NCI NIH HHS R00 CA126186
6 · The paper itself

Abstract

Recent studies have revealed the importance of multiple microRNAs (miRNAs) in promoting tumorigenesis, among which mir-17-92/Oncomir-1 exhibits potent oncogenic activity. Genomic amplification and elevated expression of mir-17-92 occur in several human B-cell lymphomas, and enforced mir-17-92 expression in mice cooperates with c-myc to promote the formation of B-cell lymphomas. Unlike classic protein-coding oncogenes, mir-17-92 has an unconventional gene structure, where one primary transcript yields six individual miRNAs. Here, we functionally dissected the individual components of mir-17-92 by assaying their tumorigenic potential in vivo. Using the Emu-myc model of mouse B-cell lymphoma, we identified miR-19 as the key oncogenic component of mir-17-92, both necessary and sufficient for promoting c-myc-induced lymphomagenesis by repressing apoptosis. The oncogenic activity of miR-19 is at least in part due to its repression of the tumor suppressor Pten. Consistently, miR-19 activates the Akt-mTOR (mammalian target of rapamycin) pathway, thereby functionally antagonizing Pten to promote cell survival. Our findings reveal the essential role of miR-19 in mediating the oncogenic activity of mir-17-92, and implicate the functional diversity of mir-17-92 components as the molecular basis for its pleiotropic effects during tumorigenesis.

Indexed as

AnimalsB-LymphocytesCell SurvivalGene Expression Regulation, NeoplasticLymphomaMiceMicroRNAsNIH 3T3 CellsOncogene Protein v-aktOncogenesProtein KinasesPTEN PhosphohydrolaseTOR Serine-Threonine KinasesMicroRNAsMTOR protein, humanmTOR protein, mouseOncogene Protein v-aktProtein KinasesPTEN PhosphohydrolaseTOR Serine-Threonine Kinases

Identifiers

PMID20008935
PMCPMC2800084
OpenAlexW2116365126

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.